A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 977 participants.
Also called NCT01294683
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 977 participants
- Sponsor
- Registry
-
NCT01294683 -
2010-023939-42
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01294683. Randomized; double masking; primary purpose treatment. Start 2011-02-04 (actual); primary completion 2012-01-17 (actual). Results posted on 2016-12-13.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
- Condition
- Primary Hypercholesterolemia
- Condition
- Dyslipidemia
- Intervention (Drug)
- Simvastatin
- Intervention (Drug)
- Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)
- Intervention (Drug)
- Extended Release (ER) niacin/laropiprant (N/LRPT)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01294683- Content hash
2b769befbc78bd1f2b927ef36ac973e2bca087757d0eb81b519cb11dc55122b1